Dr. Molly Fisher, D.O
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,422 | 45 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $279.78 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $251.37 | 2 | $0 (2017) |
| AKEBIA THERAPEUTICS INC | $188.21 | 10 | $0 (2022) |
| Amgen Inc. | $116.88 | 5 | $0 (2020) |
| Genentech USA, Inc. | $113.56 | 1 | $0 (2019) |
| Relypsa, Inc. | $112.97 | 7 | $0 (2020) |
| PFIZER INC. | $59.55 | 1 | $0 (2017) |
| Takeda Pharmaceuticals America, Inc. | $56.06 | 4 | $0 (2017) |
| Vertex Pharmaceuticals Incorporated | $55.92 | 1 | $0 (2022) |
| Mallinckrodt LLC | $38.49 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $279.78 | 3 | Gilead Sciences, Inc. ($279.78) |
| 2022 | $99.13 | 4 | Vertex Pharmaceuticals Incorporated ($55.92) |
| 2021 | $50.23 | 3 | AKEBIA THERAPEUTICS INC ($25.44) |
| 2020 | $119.92 | 5 | Amgen Inc. ($55.50) |
| 2019 | $221.50 | 6 | Genentech USA, Inc. ($113.56) |
| 2018 | $24.59 | 2 | Relypsa, Inc. ($13.14) |
| 2017 | $627.16 | 22 | Alexion Pharmaceuticals, Inc. ($251.37) |
All Payment Transactions
45 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $137.33 | General |
| 03/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $140.33 | General |
| 03/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.12 | General |
| 11/04/2022 | Vertex Pharmaceuticals Incorporated | — | Food and Beverage | In-kind items and services | $55.92 | General |
| 10/06/2022 | AKEBIA THERAPEUTICS INC | Auryxia (Drug) | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: Nephrology | ||||||
| 06/28/2022 | AKEBIA THERAPEUTICS INC | Auryxia (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Nephrology | ||||||
| 05/10/2022 | AKEBIA THERAPEUTICS INC | Auryxia (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Nephrology | ||||||
| 11/09/2021 | Ultragenyx Pharmaceutical Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
| 05/04/2021 | AKEBIA THERAPEUTICS INC | Auryxia (Drug) | Food and Beverage | In-kind items and services | $11.15 | General |
| Category: Nephrology | ||||||
| 01/12/2021 | AKEBIA THERAPEUTICS INC | Auryxia (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Nephrology | ||||||
| 10/27/2020 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: NEPHROLOGY | ||||||
| 09/03/2020 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $29.43 | General |
| Category: Nephrology | ||||||
| 05/20/2020 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $26.07 | General |
| Category: Nephrology | ||||||
| 02/28/2020 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Hyperkalemia | ||||||
| 01/27/2020 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: NEPHROLOGY | ||||||
| 11/19/2019 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | Cash or cash equivalent | $24.98 | General |
| Category: NEPHROLOGY | ||||||
| 11/15/2019 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.08 | General |
| Category: NEPHROLOGY | ||||||
| 11/15/2019 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $11.67 | General |
| Category: Nephrology | ||||||
| 10/25/2019 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.11 | General |
| Category: NEPHROLOGY | ||||||
| 10/11/2019 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: Nephrology | ||||||
| 03/12/2019 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $113.56 | General |
| 04/09/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Hyperkalemia | ||||||
| 01/25/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Uloric (Drug) | Food and Beverage | In-kind items and services | $11.45 | General |
| Category: Gout/Rheumatology | ||||||
| 12/21/2017 | Takeda Pharmaceuticals America, Inc. | Uloric (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Gout/Rheumatology | ||||||
| 12/18/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 112 | 211 | $274,018 | $35,690 |
| 2022 | 7 | 128 | 224 | $291,098 | $44,353 |
| 2021 | 8 | 313 | 554 | $584,321 | $76,334 |
| 2020 | 11 | 396 | 691 | $704,269 | $97,816 |
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 13 | 54 | $104,770 | $14,560 | 13.9% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 11 | 32 | $78,400 | $10,380 | 13.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 63 | $33,705 | $4,528 | 13.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 33 | $20,675 | $3,541 | 17.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $18,398 | $1,825 | 9.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 13 | 13 | $18,070 | $856.18 | 4.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 18 | 57 | $121,695 | $19,395 | 15.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 21 | 48 | $83,520 | $13,493 | 16.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 43 | $24,725 | $4,177 | 16.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $19,813 | $2,646 | 13.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 23 | 29 | $15,515 | $1,918 | 12.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 20 | $10,100 | $1,839 | 18.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 11 | 13 | $15,730 | $885.02 | 5.6% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 20 | 105 | $224,175 | $35,553 | 15.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 60 | 119 | $63,865 | $11,537 | 18.1% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 57 | 108 | $130,680 | $7,355 | 5.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 77 | 106 | $55,690 | $7,136 | 12.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 32 | 32 | $45,731 | $5,781 | 12.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 35 | 35 | $40,245 | $4,512 | 11.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 21 | 31 | $15,475 | $2,839 | 18.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 18 | $8,460 | $1,621 | 19.2% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 35 | 131 | $261,740 | $34,504 | 13.2% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2020 | 39 | 88 | $121,880 | $19,536 | 16.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 67 | 150 | $72,444 | $14,422 | 19.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 42 | 42 | $55,110 | $7,690 | 14.0% |
About Dr. Molly Fisher, D.O
Dr. Molly Fisher, D.O is a Student in an Organized Health Care Education/Training Program healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2011. The National Provider Identifier (NPI) number assigned to this provider is 1467749143.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Molly Fisher, D.O has received a total of $1,422 in payments from pharmaceutical and medical device companies, with $279.78 received in 2024. These payments were reported across 45 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($1,422).
As a Medicare-enrolled provider, Fisher has provided services to 949 Medicare beneficiaries, totaling 1,680 services with total Medicare billing of $254,193. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Nephrology
- Location Bronx, NY
- Active Since 07/01/2011
- Last Updated 03/18/2019
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1467749143
Products in Payments
- SOLIRIS (Drug) $251.37
- AURYXIA (Drug) $119.56
- Veltassa (Drug) $112.97
- Auryxia (Drug) $81.63
- Uloric (Drug) $67.51
- Parsabiv (Biological) $61.38
- ELIQUIS (Drug) $59.55
- Parsabiv (Drug) $55.50
- ACTHAR (Biological) $38.49
- Edarbi (Drug) $29.46
- Crysvita (Drug) $24.79
- RENVELA (Drug) $23.71
- ZEPATIER (Drug) $19.73
- SAMSCA (Drug) $14.60
- ENTRESTO (Drug) $12.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Bronx
Dr. David Altschul, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $394,687
Edvard Skripochnik, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $127,559
Dr. Cynthia Armand
Student in an Organized Health Care Education/Training Program — Payments: $68,024
Dr. Eric Woods, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $40,336
Ms. Kavita Gupta, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $31,772
Dr. Dmitriy Nevelev, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $30,107